7-Day Free Trial

Get 7 days FREE access to ALL funding rounds in real-time

Start your free trial now - no credit card required. Get real-time alerts, AI-matched leads, and our proprietary scoring system.

✓ 7-day free trial with FULL access • ✓ Real-time Chrome & Slack alerts • ✓ Companies & Industries dashboard

Your 7-day trial includes:

✓ FULL Starter features

✓ Real-time data & alerts

✓ 10 AI-matched leads daily

No credit card • Full access • Cancel anytime

Neuropathix, Inc. announced it raised $1.21 Million in an initial filing from an offering of $1.21 Million

Feb 23, 2021•over 4 years ago

Amount Raised

$1.21 Million

Round Type

seed

DoylestownHealthcare

Company Information

Company

NEUROPATHIX, INC.

Location

3805 OLD EASTON ROAD

Doylestown, Pennsylvania, United States

About

KannaLife Sciences, Inc. is a bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. KannaLife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer (NIH-OTT) for the Commercialization of U.S. Patent 6,630,507, Cannabinoids as Antioxidants and Neuroprotectants (the 507 Patent). KannaLife is currently conducting research and development at the Bucks County Biotechnology Center in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy (HE). HE is an oxidative stress related disease that affects the cognitive and behavioral functions, and the wellness of the brain. #6630507, 6630507

Neuropathix, Inc. announced it raised $1.21 Million in an initial filing from an offering of $1.21 Million

Company Information

FundzWatch™ Score

Buyer Intent Analysis

Related People